StockNews.com Begins Coverage on Check-Cap (NASDAQ:CHEK)

Equities research analysts at StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note issued to investors on Saturday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Down 1.0 %

Shares of NASDAQ:CHEK opened at $2.03 on Friday. The firm’s 50 day moving average price is $2.14 and its 200 day moving average price is $2.19. The stock has a market cap of $11.88 million, a price-to-earnings ratio of -0.68 and a beta of 0.40. Check-Cap has a fifty-two week low of $1.78 and a fifty-two week high of $4.63.

Check-Cap (NASDAQ:CHEK) last announced its quarterly earnings results on Wednesday, May 15th. The medical research company reported ($0.62) EPS for the quarter. On average, equities analysts anticipate that Check-Cap will post -0.68 EPS for the current year.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.